Filtros : "FCF004" "Current Drug Targets" Removidos: "Parra, José Roberto Postali" "Guanabara Koogan Ltda." Limpar

Filtros



Refine with date range


  • Source: Current Drug Targets. Unidade: FCF

    Subjects: FLAVONOIDES, MEDICAMENTO, DOENÇAS NEGLIGENCIADAS

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      PONE, Boniface Kamdem e FERREIRA, Elizabeth Igne. Therapeutic potential of flavonoid derivatives for certain neglected tropical diseases [Editorial]. Current Drug Targets. Sharjah: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://doi.org/10.2174/1389450123666220309093827. Acesso em: 29 set. 2024. , 2022
    • APA

      Pone, B. K., & Ferreira, E. I. (2022). Therapeutic potential of flavonoid derivatives for certain neglected tropical diseases [Editorial]. Current Drug Targets. Sharjah: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.2174/1389450123666220309093827
    • NLM

      Pone BK, Ferreira EI. Therapeutic potential of flavonoid derivatives for certain neglected tropical diseases [Editorial] [Internet]. Current Drug Targets. 2022 ; 23( 7): 680-682.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450123666220309093827
    • Vancouver

      Pone BK, Ferreira EI. Therapeutic potential of flavonoid derivatives for certain neglected tropical diseases [Editorial] [Internet]. Current Drug Targets. 2022 ; 23( 7): 680-682.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450123666220309093827
  • Source: Current Drug Targets. Unidade: FCF

    Subjects: TRYPANOSOMA CRUZI, COMPOSTOS HETEROCÍCLICOS, ANTIPROTOZOÁRIOS, DOENÇAS NEGLIGENCIADAS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      PONE, Kamdem Boniface et al. Triazole-containing heterocycles: privileged scaffolds in anti-Trypanosoma cruzi drug development. Current Drug Targets, v. 23, n. 1, p. 33-59, 2022Tradução . . Disponível em: https://doi.org/10.2174/1389450122666210412125643. Acesso em: 29 set. 2024.
    • APA

      Pone, K. B., Dalhatou, S., Paumo, H. K., Seru, L. M. K., & Ferreira, E. I. (2022). Triazole-containing heterocycles: privileged scaffolds in anti-Trypanosoma cruzi drug development. Current Drug Targets, 23( 1), 33-59. doi:10.2174/1389450122666210412125643
    • NLM

      Pone KB, Dalhatou S, Paumo HK, Seru LMK, Ferreira EI. Triazole-containing heterocycles: privileged scaffolds in anti-Trypanosoma cruzi drug development [Internet]. Current Drug Targets. 2022 ; 23( 1): 33-59.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450122666210412125643
    • Vancouver

      Pone KB, Dalhatou S, Paumo HK, Seru LMK, Ferreira EI. Triazole-containing heterocycles: privileged scaffolds in anti-Trypanosoma cruzi drug development [Internet]. Current Drug Targets. 2022 ; 23( 1): 33-59.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450122666210412125643
  • Source: Current Drug Targets. Unidade: FCF

    Subjects: DOENÇAS NEGLIGENCIADAS, ANTIMALÁRICOS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      BONIFACE, Pone Kamdem e FERREIRA, Elizabeth Igne. The role of nitro (NO 2-), Chloro (Cl), and Fluoro (F) substitution in the design of antileishmanial and antichagasic compounds. Current Drug Targets, v. 22, p. 379-398, 2021Tradução . . Disponível em: https://doi.org/10.2174/1389450121666201228122239. Acesso em: 29 set. 2024.
    • APA

      Boniface, P. K., & Ferreira, E. I. (2021). The role of nitro (NO 2-), Chloro (Cl), and Fluoro (F) substitution in the design of antileishmanial and antichagasic compounds. Current Drug Targets, 22, 379-398. doi:10.2174/1389450121666201228122239
    • NLM

      Boniface PK, Ferreira EI. The role of nitro (NO 2-), Chloro (Cl), and Fluoro (F) substitution in the design of antileishmanial and antichagasic compounds [Internet]. Current Drug Targets. 2021 ; 22 379-398.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450121666201228122239
    • Vancouver

      Boniface PK, Ferreira EI. The role of nitro (NO 2-), Chloro (Cl), and Fluoro (F) substitution in the design of antileishmanial and antichagasic compounds [Internet]. Current Drug Targets. 2021 ; 22 379-398.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450121666201228122239
  • Source: Current Drug Targets. Unidade: FCF

    Subjects: FILARIOSE, DOENÇAS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      BONIFACE, Pone Kamdem e FERREIRA, Elizabeth Igne. An insight into the discovery of potent Antifilarial leads against lymphatic filariasis. Current Drug Targets, v. 21, p. 657-680, 2020Tradução . . Disponível em: https://doi.org/10.2174/1389450120666191204152415. Acesso em: 29 set. 2024.
    • APA

      Boniface, P. K., & Ferreira, E. I. (2020). An insight into the discovery of potent Antifilarial leads against lymphatic filariasis. Current Drug Targets, 21, 657-680. doi:10.2174/1389450120666191204152415
    • NLM

      Boniface PK, Ferreira EI. An insight into the discovery of potent Antifilarial leads against lymphatic filariasis [Internet]. Current Drug Targets. 2020 ; 21 657-680.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450120666191204152415
    • Vancouver

      Boniface PK, Ferreira EI. An insight into the discovery of potent Antifilarial leads against lymphatic filariasis [Internet]. Current Drug Targets. 2020 ; 21 657-680.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450120666191204152415
  • Source: Current Drug Targets. Unidade: FCF

    Subjects: LEISHMANIA, FARMACOLOGIA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      BONIFACE, Pone Kamdem e SANO, Cinthya Miyuki e FERREIRA, Elizabeth Igne. Unveiling the targets involved in the quest of antileishmanial Leads using in silico methods. Current Drug Targets, v. 21, p. 681-712, 2020Tradução . . Disponível em: https://doi.org/10.2174/1389450121666200128112948. Acesso em: 29 set. 2024.
    • APA

      Boniface, P. K., Sano, C. M., & Ferreira, E. I. (2020). Unveiling the targets involved in the quest of antileishmanial Leads using in silico methods. Current Drug Targets, 21, 681-712. doi:10.2174/1389450121666200128112948
    • NLM

      Boniface PK, Sano CM, Ferreira EI. Unveiling the targets involved in the quest of antileishmanial Leads using in silico methods [Internet]. Current Drug Targets. 2020 ; 21 681-712.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450121666200128112948
    • Vancouver

      Boniface PK, Sano CM, Ferreira EI. Unveiling the targets involved in the quest of antileishmanial Leads using in silico methods [Internet]. Current Drug Targets. 2020 ; 21 681-712.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450121666200128112948
  • Source: Current Drug Targets. Unidades: ICB, FCF, EACH

    Subjects: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, SÍNDROME X METABÓLICA, ÁCIDOS GRAXOS, DOENÇAS METABÓLICAS, PARASITOLOGIA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      MALTAROLLO, Vinícius Gonçalves et al. Advances and challenges in drug design of PPARδ ligands. Current Drug Targets, v. 19, n. 2, p. 144-154, 2018Tradução . . Disponível em: https://doi.org/10.2174/1389450118666170414113159. Acesso em: 29 set. 2024.
    • APA

      Maltarollo, V. G., Kronenberger, T., Windshuegel, B., Wrenger, C., Trossini, G. H. G., & Honório, K. M. (2018). Advances and challenges in drug design of PPARδ ligands. Current Drug Targets, 19( 2), 144-154. doi:10.2174/1389450118666170414113159
    • NLM

      Maltarollo VG, Kronenberger T, Windshuegel B, Wrenger C, Trossini GHG, Honório KM. Advances and challenges in drug design of PPARδ ligands [Internet]. Current Drug Targets. 2018 ; 19( 2): 144-154.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450118666170414113159
    • Vancouver

      Maltarollo VG, Kronenberger T, Windshuegel B, Wrenger C, Trossini GHG, Honório KM. Advances and challenges in drug design of PPARδ ligands [Internet]. Current Drug Targets. 2018 ; 19( 2): 144-154.[citado 2024 set. 29 ] Available from: https://doi.org/10.2174/1389450118666170414113159

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024